Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fox, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fox, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Poststroke patients: implications for the cardiologist

K. Fox*

Royal Brompton Hospital, London, U.K.

* Kim Fox, Royal Bromptom & National Heart and Lung Hospital, Department of Cardiology, Sydney Street, London SW3 6NP, U.K.

Abstract

PROGRESS (Perindopril pROtection aGainst REcurrent Stroke Study) was the first trial specifically designed to determine the effects of blood pressure lowering on stroke and cardiac events among patients with a history of cerebrovascular disease, regardless of age, sex, ethnicity, concomitant therapy or blood pressure. A total of 6105 individuals with previous stroke or transient ischaemic attack were randomly assigned to receive active treatment with the angiotensin-converting enzyme inhibitor perindopril (4 mg/day), with the addition of the diuretic indapamide at the discretion of treating physicians. After 4 years of follow-up, perindopril-based therapy not only reduced the risk for stroke by 28% () but also reduced the risk for total coronary events by 21% (), including a 38% reduction in non-fatal myocardial infarction, and the risk for congestive heart failure by 26% (). Both stroke and ischaemic heart disease make huge contributions to the overall global burden of disease, and so these positive results should have major implications for cardiovogists. In addition, heart failure is more common in patients with vascular disease, and represents a further and increasing public health problem in industrialized countries with ageing populations. Finally, the management of patients with previous stroke and normal blood pressure remained an unmet medical need in clinical medicine. PROGRESS has demonstrated that a perindopril-based regimen is of clinical importance for preventing stroke and cardiac events in both hypertensive and non-hypertensive patients with stroke or transient ischaemic attack.

Key Words: Blood pressure • Heart failure • Indapamide • Myocardial infarction • Perindopril • Stroke


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.